FDA Panel Says Obesity Drugs Need Tougher Clinical Trials
A U.S. Food and Drug Administration advisory committee reportedly recommended toughening its clinical trial requirements for obesity drugs on Thursday, requiring companies to test specifically for cardiovascular risks before receiving approval....To view the full article, register now.
Already a subscriber? Click here to view full article